Could a single fixed dose stop brain bleeds in patients on blood thinners?

NCT ID NCT06096051

Completed Disease control Sponsor: Methodist Health System Source: ClinicalTrials.gov ↗

First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This completed study looked at whether a fixed dose of a drug called 4F-PCC is safe and effective for reversing the effects of common blood thinners (rivaroxaban or apixaban) in patients with brain bleeding. Researchers compared this fixed-dose approach to the standard weight-based dosing in 76 adults. The goal was to see if the simpler fixed dose could control bleeding just as well.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: 4-factor prothrombin complex concentrate (4F-PCC)
What this could lead to: If successful, this could simplify emergency treatment for brain bleeding in patients on common blood thinners, potentially saving lives.
What could go wrong: This is a small, completed study with only 76 participants. Results may not apply to all patients, and the fixed dose may not work as well as weight-based dosing in some cases.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for INTRACRANIAL HEMORRHAGE are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

intracerebral hemorrhage Intracranial Hemorrhages

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

INTRACRANIAL HEMORRHAGE

Contacts and locations

Locations

Methodist Dallas Medical Center

Dallas, Texas, 75203, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.